دورية أكاديمية
Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012-2021.
| العنوان: | Antithrombotic Therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012-2021. |
|---|---|
| المؤلفون: | Stevens SM; Department of Medicine, Intermountain Health, Murray, UT; Department of Internal Medicine, Univeristy of Utah School of Medicine, Salt Lake City, UT., Woller SC; Department of Medicine, Intermountain Health, Murray, UT; Department of Internal Medicine, Univeristy of Utah School of Medicine, Salt Lake City, UT., Baumann Kreuziger L; Versiti Blood Research Institute and Medical College of Wisconsin, Milwaukee, WI., Doerschug K; Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA., Geersing GJ; Julius Center for Health Sciences and Primary Care, Department of General Practice and Nursing Science, University Medical Center Utrecht, Utrecht., Klok FA; Department of Medicine-Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands., King CS; Advanced Lung Disease and Transplant Clinic, Inova Fairfax Hospital, Falls Church, VA., Murin S; University of California Davis School of Medicine, Sacramento, CA., Vintch JRE; Lundquist Institute for Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, CA., Wells PS; Department of Medicine, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada., Wasan S; Department of Medicine, University of North Carolina, Chapel Hill, NC., Moores LK; Department of Medicine, F. Edward Hebert School of Medicine, The Uniformed Services University of the Health Sciences, Bethesda MD. |
| المصدر: | Chest [Chest] 2024 Aug; Vol. 166 (2), pp. 388-404. Date of Electronic Publication: 2024 Mar 06. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 0231335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1931-3543 (Electronic) Linking ISSN: 00123692 NLM ISO Abbreviation: Chest Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2016- : New York : Elsevier Original Publication: Chicago : American College of Chest Physicians |
| مواضيع طبية MeSH: | Fibrinolytic Agents*/therapeutic use , Venous Thromboembolism*/drug therapy, Humans ; Anticoagulants/therapeutic use ; Evidence-Based Medicine ; Practice Guidelines as Topic |
| مستخلص: | The American College of Chest Physicians (CHEST) Antithrombotic Therapy for Venous Thromboembolism Disease evidence-based guidelines are now updated in a more frequent, focused manner. Guidance statements from the most recent full guidelines and two subsequent updates have not been gathered into a single source. An international panel of experts with experience in prior antithrombotic therapy guideline development reviewed the 2012 CHEST antithrombotic therapy guidelines and its two subsequent updates. All guideline statements and their associated patient, intervention, comparator, and outcome questions were assembled. A modified Delphi process was used to select statements considered relevant to current clinical care. The panel further endorsed minor phrasing changes to match the standard language for guidance statements using the modified Grading of Recommendations, Assessment, Development, and Evaluations (ie, GRADE) format endorsed by the CHEST Guidelines Oversight Committee. The panel appended comments after statements deemed as relevant, including suggesting that statements be updated in future guidelines because of interval evidence. We include 58 guidance statements from prior versions of the antithrombotic therapy guidelines, with updated phrasing as needed to adhere to contemporary nomenclature. Statements were classified as strong or weak recommendations based on high-certainty, moderate-certainty, and low-certainty evidence using GRADE methodology. The panel suggested that five statements are no longer relevant to current practice. As CHEST continues to update guidance statements relevant to antithrombotic therapy for VTE disease, this article serves as a unified collection of currenrtly relevant statements from the preceding three guidelines. Suggestions have been made to update specific statements in future publications. Competing Interests: Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: L. B. K. reports receiving research funding from CSL Behring and Takeda to her institution for unrelated research. None declared S. M. S., S. C. W., K. D., G.-J. G., F. A. K., C. S. K., S. M., J. R. E. V., P. S. W., S. W., and L. K. M. (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: DVT; VTE; anticoagulant; guideline; pulmonary embolism; treatment |
| المشرفين على المادة: | 0 (Anticoagulants) 0 (Fibrinolytic Agents) |
| تواريخ الأحداث: | Date Created: 20240308 Date Completed: 20240809 Latest Revision: 20240812 |
| رمز التحديث: | 20240813 |
| DOI: | 10.1016/j.chest.2024.03.003 |
| PMID: | 38458430 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1931-3543 |
|---|---|
| DOI: | 10.1016/j.chest.2024.03.003 |